The estimated Net Worth of Jiny Kim is at least $77.8 Thousand dollars as of 13 December 2023. Jiny Kim owns over 7,519 units of Cytosorbents Corp stock worth over $77,819 and over the last 3 years Jiny sold CTSO stock worth over $0.
Jiny has made over 2 trades of the Cytosorbents Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently Jiny bought 7,519 units of CTSO stock worth $10,000 on 13 December 2023.
The largest trade Jiny's ever made was buying 7,519 units of Cytosorbents Corp stock on 13 December 2023 worth over $10,000. On average, Jiny trades about 1,420 units every 79 days since 2022. As of 13 December 2023 Jiny still owns at least 77,819 units of Cytosorbents Corp stock.
You can see the complete history of Jiny Kim stock trades at the bottom of the page.
Jiny's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus, and Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: